XSpray Financial Statements From 2010 to 2024
| XSPRAY Stock | SEK 41.40 1.10 2.59% |
Check XSpray Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XSpray Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . XSpray financial statements analysis is a perfect complement when working with XSpray Pharma Valuation or Volatility modules.
XSpray |
XSpray Pharma AB Company Shares Owned By Insiders Analysis
XSpray Pharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current XSpray Pharma Shares Owned By Insiders | 47.42 % |
Most of XSpray Pharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XSpray Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 47.42% of XSpray Pharma AB are shares owned by insiders. This is 212.38% higher than that of the Healthcare sector and 234.41% higher than that of the Biotechnology industry. The shares owned by insiders for all Sweden stocks is notably lower than that of the firm.
XSpray Pharma AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining XSpray Pharma's current stock value. Our valuation model uses many indicators to compare XSpray Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XSpray Pharma competition to find correlations between indicators driving XSpray Pharma's intrinsic value. More Info.XSpray Pharma AB is rated second in return on equity category among its peers. It is rated second in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value XSpray Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for XSpray Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About XSpray Pharma Financial Statements
XSpray Pharma stakeholders use historical fundamental indicators, such as XSpray Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although XSpray Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in XSpray Pharma's assets and liabilities are reflected in the revenues and expenses on XSpray Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in XSpray Pharma AB. Please read more on our technical analysis and fundamental analysis pages.
Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in XSpray Stock
XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.